BOSTON
and LAUSANNE, Switzerland, Jan.
10, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq:
SOPH), the creator of a global data pooling and knowledge sharing
platform that advances data-driven medicine, announced key
additions to their leadership team with the hiring of Peter
Casasanto as Chief BioPharma Officer and Abhimanyu (Abhi)
Verma as Chief Technology Officer. The additions are part of
SOPHiA GENETICS' strategy to enhance its business in the
pharmaceutical industry. Peter and Abhi will help the company drive
deeper with a focus on leveraging data for the BioPharma
industry.
"We have undergone considerable growth in recent months with
exciting expansions to our global footprint and BioPharma
business," said Jurgi Camblong, co-founder and CEO of SOPHiA
GENETICS. "Placing a priority on BioPharma and technology
innovation will drive our overall vision to support and accelerate
the evolving data research needs of healthcare institutions around
the world. Peter and Abhi bring diverse insights and leadership
experience, and their expertise will be vital to ensuring we
deliver on this vision."
Peter brings more than 15 years of life sciences industry
experience in business development and sales strategy to SOPHiA
GENETICS' growing portfolio. Prior to this role, he was Vice
President of New Commercialization Initiatives at CellCarta where
he led commercial strategies for corporate initiatives, including
companion diagnostics/single-site IVD launch and Go-to-Market
strategy for an in-house developed SaaS analytics platform, as well
as AI-driven initiatives for multiomic-based insights and
predictions. Peter also held corporate and business development
roles at Tempus Labs, NeoGenomics and LabCorp. He started his
career as a scientist at Merck's Vaccines & Biologics Lab,
eventually moving on to lead business development efforts for PPD's
newly acquired vaccines division.
Abhi brings more than 17 years of Life Sciences industry
experience in leading global multifunctional organizations to
develop technology and data driven capabilities and platforms to
accelerate drug R&D and patient access to breakthrough
therapies. Previously, Abhi served at Novartis where he had several
leadership roles spanning multiple functions, locations and therapy
areas in applied technology innovation, real world evidence, drug
development, enterprise technologies, IT strategy, data science and
AI. He incubated and scaled several technology and data centric
platforms, products and capabilities that underpin the digital
transformation at Novartis. The early part of his career was spent
at GE and Patni Computers.
"I am excited and incredibly proud to join an organization that
is taking such a thoughtful approach to harnessing and
standardizing complex genotypic, radiomic and phenotypic datasets
to advance both patient care and drug development," said
Peter. "Having previously been a part of an organization with a
centralized focus, I've seen first-hand the importance of a more
decentralized approach to capture data globally. Big data and
machine learning will significantly impact the healthcare
ecosystem, but without an intelligent analytics platform to
harmonize and make sense of the data, the utility will be
limited. Having a platform like SOPHiA DDM that leverages a
global network will be increasingly important to accelerate
recruitment and site selection and enhance trial design and
targeted patient selection."
"As someone who is motivated by creating impact on patients, I
am tremendously excited and humbled to have the opportunity to be
part of a team and culture that is intellectually honest,
passionate, grounded, and is taking a precision approach towards
multimodal insights to support healthcare institutions and
accelerate R&D," said Abhi. "The Sophia DDM platform is unique
in its capabilities, as it can bring together diverse datasets to
generate multi modal disease and patient insights powered by AI
while enabling the sharing of knowledge and insights across the
clinical research and healthcare community. I am joining a
team that is responding to very complex challenges, and I look
forward to being part of the journey to further drive and
accelerate the technology innovation and product development."
Peter holds an MBA in Pharmaceutical Management from Drexel's
LeBow College of Business, a Master
of Science degree in Biomedical Chemistry from Thomas Jefferson
Medical School, and a Bachelor of Science degree in Immunology
& Genomics from the University of Maryland
at College Park.
Abhi holds an MBA from the Indian School of
Business, a Master of Science degree in Pharmaceutical
Medicine, and is an Engineer. He is also co-founder of the
non-profit Health Hacking Lab.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/executive-team-hires-at-sophia-genetics-to-enhance-biopharma-business-301456604.html
SOURCE SOPHiA GENETICS